These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 24650147)

  • 1. Semi-physiological pharmacokinetic-pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil and lymphocyte counts in rats.
    Kobuchi S; Ito Y; Hayakawa T; Kuwano S; Baba A; Shinohara K; Nishimura A; Shibata N; Takada K
    Xenobiotica; 2014 Sep; 44(9):804-18. PubMed ID: 24650147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats.
    Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
    J Pharmacol Toxicol Methods; 2014; 70(2):134-44. PubMed ID: 25072509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semi-physiological pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for thrombocytopenia in rats.
    Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
    Xenobiotica; 2015 Jan; 45(1):19-28. PubMed ID: 25050790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.
    Friberg LE; Freijs A; Sandström M; Karlsson MO
    J Pharmacol Exp Ther; 2000 Nov; 295(2):734-40. PubMed ID: 11046112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats.
    Kobuchi S; Ito Y; Sakaeda T
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):707-718. PubMed ID: 27889876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of oxaliplatin for hematological toxicity in rats.
    Kobuchi S; Katsuyama Y; Ito Y
    Xenobiotica; 2020 Feb; 50(2):223-230. PubMed ID: 30938550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information.
    Wallin JE; Friberg LE; Karlsson MO
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):234-42. PubMed ID: 20050841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
    Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-induced myelosuppression by vinorelbine: a comparison between different dose schedules by simulation.
    Urso R; Nencini C; Giorgi G; Fiaschi AI
    Eur Rev Med Pharmacol Sci; 2007; 11(6):413-7. PubMed ID: 18306910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive marker for exposure-driven haematological toxicity of tegafur-uracil and proposed modified-dosage regimen by pharmacometric approach in rats.
    Kobuchi S; Matsui M; Ito Y
    Xenobiotica; 2022 Jul; 52(7):697-706. PubMed ID: 36412205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
    Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
    Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nociceptive stimulus modality-related difference in pharmacokinetic-pharmacodynamic modeling of morphine in the rat.
    Shang GW; Liu DN; Yan LH; Cui XY; Zhang KP; Qi C; Chen J
    Pharmacol Biochem Behav; 2006 Oct; 85(2):464-73. PubMed ID: 17126387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension.
    Bertera FM; Mayer MA; Opezzo JA; Taira CA; Höcht C
    J Pharmacol Toxicol Methods; 2008; 57(3):212-9. PubMed ID: 18442930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
    Friberg LE; Henningsson A; Maas H; Nguyen L; Karlsson MO
    J Clin Oncol; 2002 Dec; 20(24):4713-21. PubMed ID: 12488418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
    Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
    Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic pharmacokinetic-pharmacodynamic modeling of BACE1 inhibition in monkeys: development of a predictive model for amyloid precursor protein processing.
    Liu X; Wong H; Scearce-Levie K; Watts RJ; Coraggio M; Shin YG; Peng K; Wildsmith KR; Atwal JK; Mango J; Schauer SP; Regal K; Hunt KW; Thomas AA; Siu M; Lyssikatos J; Deshmukh G; Hop CE
    Drug Metab Dispos; 2013 Jul; 41(7):1319-28. PubMed ID: 23584887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma.
    Daryani VM; Patel YT; Tagen M; Turner DC; Carcaboso AM; Atkinson JM; Gajjar A; Gilbertson RJ; Wright KD; Stewart CF
    CPT Pharmacometrics Syst Pharmacol; 2016 Apr; 5(4):211-221. PubMed ID: 27104090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip.
    Sung JH; Kam C; Shuler ML
    Lab Chip; 2010 Feb; 10(4):446-55. PubMed ID: 20126684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.
    Latz JE; Rusthoven JJ; Karlsson MO; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):427-35. PubMed ID: 16322992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitor.
    Saito T; Iida S; Abe M; Jones K; Kawanishi T; Twelves C
    J Pharm Pharmacol; 2013 Aug; 65(8):1168-78. PubMed ID: 23837584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.